SEC 13F Intelligence

Managers / Q4 2019

VHCP Management II, LLC

CIK 0001602263 · 7 BRYANT PARK, 23RD FLOOR, NEW YORK, NY, 10018 · 650 475 3734

Reported Value
$379M
Q4 2019
Positions
20
Filings on Record
4
2019–present window
Filed
Feb 13, 2020
original filing

Summary

Vhcp Management II, LLC reported $379M in U.S.-listed holdings across 20 positions for Q4 2019.

The portfolio is heavily concentrated: TXG alone accounts for 35.9% of reported value.

Compared with Q3 2019, the fund opened 8 new positions and exited 9.

Portfolio Metrics

Turnover
+28.6%
vs prior filed quarter
Top-10 Concentration
+94.1%
share of reported value
Largest Position
+35.9%
10x Genomics
New / Exited
8 / 9
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $342MQ1 ’19Q2 ’19: $317MQ2 ’19Q3 ’19: $262MQ3 ’19Q4 ’19: $379MQ4 ’19filingsflow.com

Portfolio Composition

By security type
Common Stock: 90.1%Other: 9.9%
  • Common Stock · 90.1% · $342M
  • Other · 9.9% · $38M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
Iveric Bio IncNEW+1.00M1.00M+$9M$9M
Mersana Therapeutics IncNEW+922.5K922.5K+$5M$5M
RLMDRelmada Therapeutics IncNEW+114.9K114.9K+$4M$4M
Adverum Biotechnologies IncNEW+383.6K383.6K+$4M$4M
Forty Seven IncNEW+77.7K77.7K+$3M$3M
Nextcure IncNEW+36.2K36.2K+$2M$2M
Myovant Sciences LtdNEW+76.8K76.8K+$1M$1M
89Bio IncNEW+41.2K41.2K+$1M$1M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2019

20 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1TXG10X Genomics Inc.history →COM35.91%$136M1.79M
2AXSMAxsome Therapeutics Inchistory →COM21.42%$81M786.0K
3CNSTConstellation Pharmaceuticalshistory →COM18.64%$71M1.50M
4Biohaven PharmaceuticalsCOM6.64%$25M462.9K
5Shockwave Medical IncCOM3.34%$13M288.8K
6Iveric Bio IncCOM2.27%$9M1.00M
7Kalvista PharmaceuticalsCOM1.72%$7M366.3K
8Obseva SACOM1.58%$6M1.57M
9Mersana Therapeutics IncCOM1.39%$5M922.5K
10SPROSpero Therapeutics Inchistory →COM1.20%$5M474.0K
11RLMDRelmada Therapeutics Inchistory →COM1.18%$4M114.9K
12Adverum Biotechnologies IncCOM1.16%$4M383.6K
13Marinus Pharmaceuticals IncCOM0.85%$3M1.49M
14Forty Seven IncCOM0.81%$3M77.7K
15MISTMilestone Pharmaceuticals IncCOM0.63%$2M148.6K
16Nextcure IncCOM0.54%$2M36.2K
17Myovant Sciences LtdCOM0.31%$1M76.8K
1889Bio IncCOM0.29%$1M41.2K
19Bellerophon TherapeuticsCOM0.06%$230,000659.1K
20PTGXProtagonist Therapeutics IncCOM0.06%$227,00032.2K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2019$379M20Feb 13, 202013F-HRchanges · EDGAR ↗
Q3 2019$262M21Nov 13, 201913F-HRchanges · EDGAR ↗
Q2 2019$317M21Aug 13, 201913F-HRchanges · EDGAR ↗
Q1 2019$342M21May 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.